Meeting Coverage
EHA
European Hematology Association
Granted accelerated approval last year, bispecific antibody passes its confirmatory test
Latest EHA Meeting Coverage
Undetectable MRD rates of 90% or higher, PFS of 7 years or more
All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard
Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?
ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment
Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil
Better response rates and survival with axicabtagene ciloleucel versus external control group
Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor
Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone
Anti-CD38 therapy added to conventional regimen boosts PFS in trial
Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases
Triplet regimen significantly extended median PFS versus doublet in IKEMA study
More quizartinib-treated patients went on to stem cell transplant
Preexisting aberrant B-cell clone implicated
Progression-free survival doubled with carfilzomib versus bortezomib